P1–374: Memantine and comprehensive, individualized, person‐centered management (CI‐PCM) of Alzheimer's disease: A randomized controlled trial

Reisberg, Barry; Kenowsky, Sunnie; Boksay, István; Golomb, James; Heller, Sloane; Ghimire, Santosh; Salam, Marwa; Qureshi, Sadia; Kumar, Manoj; Torossian, Carol; Vedvyas, Alok

doi:10.1016/j.jalz.2013.05.601

Cited by 2 publications

(6 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although the term nonpharmacological is both imprecise and undervalues the positive nature of such interventions, it is gaining traction in the professional literature, increasing the urgency to come up with a new label. The term is being used to describe a wide range of evidence-based programs such as caregiver training to assist in the understanding of the dementia process, 8 adaptive technologies that help the person communicate, the effects of personal care staff wearing street clothes instead of uniforms, 9 and interactive improvisational drama programs that engage persons' creativity. 10 The label nonpharmacological increasingly is being used to describe major shifts in the social milieu of persons with dementia such as counseling and support of family members to assist them to understand and live with the effects of dementia, 11 activity-based drama and art interactions in which residents choose their own subject matter, 12 and environmental interventions, such as creating home-like settings to help residents adapt more easily to change.…”

Section: Labeling: An Epistemological Challengementioning

confidence: 99%

Section: Labeling: An Epistemological Challengementioning

confidence: 99%

See 1 more Smart Citation

Ecopsychosocial Interventions in Cognitive Decline and Dementia

Zeisel

Reisberg

Whitehouse

et al. 2016

Am J Alzheimers Dis Other Demen

Self Cite

View full text Add to dashboard Cite

Dementia is a major medical and social scourge. Neither pharmacological nor nonpharmacological interventions and treatments have received sufficient funding to be meaningful in combatting this tsunami. Because the term-"nonpharmacological"-refers to what these interventions are not, rather than what they are, nonpharmacological treatments face a special set of challenges to be recognized, accepted, funded, and implemented. In some ways, the current situation is analogous to using the term "nonhate" to mean "love." This article presents a carefully reasoned argument for using the terminology "ecopsychosocial" to describe the full range of approaches and interventions that fall into this category. These include interventions such as educational efforts with care partners, social support programs for individuals with various levels of dementia, efforts to improve community awareness of dementia, an intergenerational school where persons with dementia teach young children, and the design of residential and community settings that improve functioning and can reduce behavioral symptoms of dementia. The proposed terminology relates to the nature of the interventions themselves, rather than their outcomes, and reflects the broadest range of interventions possible under the present rubric-nonpharmacological. The goal of this new label is to be better able to compare interventions and their outcomes and to be able to see the connections between data sets presently not seen as fitting together, thereby encouraging greater focus on developing new ecopsychosocial interventions and approaches that can improve the lives of those with dementia, their care partners, and the broader society.

show abstract

Section: Labeling: An Epistemological Challengementioning

confidence: 99%

Section: Labeling: An Epistemological Challengementioning

confidence: 99%

Ecopsychosocial Interventions in Cognitive Decline and Dementia

Zeisel

Reisberg

Whitehouse

et al. 2016

Am J Alzheimers Dis Other Demen

Self Cite

View full text Add to dashboard Cite

show abstract

“…More specifically, with only 10 subjects per group, significant positive effects were observed at all time points studied with the CI-PCM program (p < 0.01 at weeks 4 and 12, and p < 0.001 at week 28) [105]. Since in this CI-PCM program study, the same NYU-CIBIC-Plus measure was used as in the pivotal trial associated with the initial worldwide approval of memantine [17] and since the criteria for subject selection were very similar, it was possible to compare the magnitude of differences between these two studies which were conducted 10 years apart.…”

Section: Use Of the Behave-ad In Worldwide Studies Of Medications Appmentioning

confidence: 99%

“…However, a recent study of the efficacy of a Comprehensive, Individualized Person-Centered Management (CI-PCM) program in addition to memantine treatment versus memantine treatment alone illustrates the role of the BEHAVE-AD as an element of the NYU-CIBIC-Plus assessment [105,106]. The essential elements of the NYU-CIBIC-Plus assessment have been described previously [14] and are shown in table 3.…”

Section: Use Of the Behave-ad In Worldwide Studies Of Medications App...mentioning

confidence: 99%

“…In the study comparing the CI-PCM program plus memantine versus memantine treatment alone [105], significant improvements were observed in the NYU-CIBIC-Plus assessment in the subject group receiving the management program in comparison with the subject group which did not receive this program. More specifically, with only 10 subjects per group, significant positive effects were observed at all time points studied with the CI-PCM program (p < 0.01 at weeks 4 and 12, and p < 0.001 at week 28) [105].…”

Section: Use Of the Behave-ad In Worldwide Studies Of Medications App...mentioning

confidence: 99%

See 1 more Smart Citation

The BEHAVE-AD Assessment System: A Perspective, A Commentary on New Findings, and A Historical Review

Reisberg¹,

Monteiro²,

Torossian³

et al. 2014

Dement Geriatr Cogn Disord

Self Cite

View full text Add to dashboard Cite

Background: Behavioral and psychological symptoms of dementia (BPSD) and associated disturbances in Alzheimer's disease (AD) are a source of distress and burden for spouses, professional caregivers, and others with responsibilities for the care of individuals with AD. BPSD with behavioral disturbances are also associated with more rapid institutionalization and increased morbidity and mortality for persons with AD. Objectives: In this review and commentary, we discuss the history of the development of BPSD and behavioral disturbance assessments, which are distinct from those evaluating cognitive and functional symptoms of AD. In particular, we review the informant-based Behavioral Pathology in Alzheimer's Disease Rating Scale (BEHAVE-AD), the related, potentially more sensitive, BEHAVE-AD Frequency-Weighted Severity Scale (BEHAVE-AD-FW), and the direct subject evaluation-based Empirical BEHAVE-AD Rating Scale (E-BEHAVE-AD). The kinds of medications that alleviate behavioral symptoms on these measures as well as the problems and possibilities for further advances with these medications are discussed. Finally, the importance of distinguishing BPSD and behavioral disturbance remediation in AD from the treatment of cognitive decline and other aspects of AD is emphasized in the context of appropriate assessment methodology. The objective of this paper is to provide a framework for further advances in the treatment of BPSD and associated behavioral disturbances in AD and, consequently, a framework for continuing improvements in the lives of individuals with AD and those who share the burden of the disease with the AD person.

show abstract

P1–374: Memantine and comprehensive, individualized, person‐centered management (CI‐PCM) of Alzheimer's disease: A randomized controlled trial

Cited by 2 publications

References 0 publications

Ecopsychosocial Interventions in Cognitive Decline and Dementia

Ecopsychosocial Interventions in Cognitive Decline and Dementia

The BEHAVE-AD Assessment System: A Perspective, A Commentary on New Findings, and A Historical Review

Contact Info

Product

Resources

About